Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer

BackgroundIrreversible electroporation (IRE) is a novel local tumor ablation approach with the potential to stimulate an antitumor immune response. However, it is not effective in preventing distant metastasis in isolation. This study aimed to compare the potential of augmenting the antitumor immune...

Full description

Bibliographic Details
Main Authors:	Yangyang Ma, Yanli Xing, Hongmei Li, Ting Yuan, Bing Liang, Rongrong Li, Jianyu Li, Zhonghai Li, Shuying Li, Lizhi Niu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Immunology
Subjects:	irreversible electroporation locally advanced pancreatic cancer chemotherapy PD-1/PD-L1 blockade anticancer immunity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1193040/full

Similar Items

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

IRREVERSIBLE ELECTROPORATION FOR CANCER TREATMENT: A REVIEW
by: Tihomir Georgiev, et al.
Published: (2023-12-01)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
by: Shaomeng Chen, et al.
Published: (2021-09-01)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
by: Jihane Boustani, et al.
Published: (2021-09-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
by: Jessica M. Konen, et al.
Published: (2019-04-01)

New progress in tumor treatment based on nanoparticles combined with irreversible electroporation
by: Lei Xu, et al.
Published: (2022-10-01)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
by: Ichidai Tanaka, et al.
Published: (2021-12-01)

Uncertainty Quantification in Irreversible Electroporation Simulations
by: Nicholas Labarbera
Published: (2017-05-01)

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
by: Bai H, et al.
Published: (2024-02-01)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
by: Meng Chen, et al.
Published: (2022-11-01)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
by: Shuguang Tan, et al.
Published: (2016-11-01)

The Evidence of the Bystander Effect after Bleomycin Electrotransfer and Irreversible Electroporation
by: Paulius Ruzgys, et al.
Published: (2021-10-01)

Irreversible Electroporation for Prostate Cancer
by: Sean Ong, et al.
Published: (2021-05-01)

Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
by: Jie Peng, et al.
Published: (2022-11-01)

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
by: Tomoko Aoki, et al.
Published: (2020-10-01)

Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia
by: Francesco Romano, et al.
Published: (2020-05-01)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023-02-01)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
by: Li XY, et al.
Published: (2022-04-01)

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods
by: Yuxi Cheng, et al.
Published: (2024-02-01)

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer
by: Zhixiong Wang, et al.
Published: (2023-11-01)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
by: Huilin Ou, et al.
Published: (2022-08-01)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
by: Jia M, et al.
Published: (2022-09-01)

The First Study of Irreversible Electroporation with Calcium Ions and Chemotherapy in Patients with Locally Advanced Pancreatic Adenocarcinoma
by: Julia Rudno-Rudzińska, et al.
Published: (2020-07-01)

Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis
by: WeiWei Xiao, et al.
Published: (2022-01-01)

Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
by: Hadia Farrukh, et al.
Published: (2021-05-01)

A Single-Cell Electroporation Model for Quantitatively Estimating the Pore Area Ratio by High-Frequency Irreversible Electroporation
by: Lujia Ding, et al.
Published: (2023-01-01)

Combining an adenovirus encoding human endostatin and PD‐1 blockade enhanced antitumor immune activity
by: Yaomei Tian, et al.
Published: (2023-03-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
by: Ali Razaghi, et al.
Published: (2023-08-01)

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2023-01-01)

Irreversible Electroporation in Pancreatic Cancer—An Evolving Experimental and Clinical Method
by: Agnieszka Gajewska-Naryniecka, et al.
Published: (2023-02-01)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer
by: JIN Huimin, et al.
Published: (2022-10-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
by: Fanny Ledys, et al.
Published: (2021-11-01)

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
by: Siqing Jiang, et al.
Published: (2022-09-01)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
by: Ewa Surmiak, et al.
Published: (2021-10-01)